PMID: 21033679 , Related PDB ids: 3NBV, 3NBW, 3NC2, 3NC9, 3NCA
Gibbs AC, Abad MC, Zhang X, Tounge BA, Lewandowski FA, Struble GT, Sun W, Sui Z, Kuo LC
Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.
J Med Chem. 2010 Nov 25;53(22):7979-91. Epub 2010 Oct 29.
A fragment-based drug design paradigm has been successfully applied in the discovery of lead series of ketohexokinase inhibitors. The paradigm consists of three iterations of design, synthesis, and X-ray crystallographic screening to progress low molecular weight fragments to leadlike compounds. Applying electron density of fragments within the protein binding site as defined by X-ray crystallography, one can generate target specific leads without the use of affinity data. Our approach contrasts with most fragment-based drug design methodology where solution activity is a main design guide. Herein we describe the discovery of submicromolar ketohexokinase inhibitors with promising druglike properties.